Akshay Vaishnaw, President, R&D at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 162,108 shares at $140.45 ($23.2M) on 2018-03-14, disclosed to the SEC on 2018-03-16.
Seasonal sale ($23.2M) by President, R&D — this insider has traded ALNY in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $140.45 | 6,453 | $906K | 3.9% |
| 2 | $140.45 | 6,453 | $906K | 3.9% |
| 3 | $141.69 | 15,000 | $2.1M | 9.2% |
| 4 | $142.57 | 21,336 | $3.0M | 13.1% |
| 5 | $142.57 | 21,336 | $3.0M | 13.1% |
| 6 | $143.46 | 19,213 |
| $2.8M |
| 11.9% |
| 7 | $143.46 | 19,213 | $2.8M | 11.9% |
| 8 | $144.53 | 20,172 | $2.9M | 12.6% |
| 9 | $144.53 | 20,172 | $2.9M | 12.6% |
| 10 | $145.27 | 6,380 | $927K | 4.0% |
| 11 | $145.27 | 6,380 | $927K | 4.0% |
| Total | $143.23 avg | 162,108 | $23.2M | 100% |
| Filing → |
| SRRK | SELL | 2025-05-30 | $353K | — | Filing → |
| ALNY | SELL | 2023-08-07 | $1.4M | — | Filing → |
| ALNY | SELL | 2023-04-28 | $839K | — | Filing → |